CME & Non-CME Corporate Forum Symposia
Independently sponsored corporate forum symposia are offered in conjunction with the ASPHO 30th Annual Meeting. The programs have been reviewed and approved by the 2017 ASPHO Program Committee to ensure they are relevant to the audience and do not duplicate the official ASPHO Annual Meeting program. These satellite symposia are open to 2017 Annual Meeting registrants at no additional charge, though advance registration is required. Seating is limited and available to those responding on a first-come, first-served basis. See the registration details below.
Wednesday, April 26
11:30 am-1:00 pm
ALSF Grants Throughout Your Career: Illustrations from Immunology
Thalassemia and Sickle Cell Management: Clinical Conundrums and Interventions
Thalassemia, once a rarity in the United States, is increasingly encountered in clinical practice due to shifts in immigration. This CME-certified symposium will address the selection of individualized treatment strategies for patients with thalassemia and sickle cell thalassemia. The first part of the activity will focus on optimal transfusion and chelation, with a discussion on bone marrow transplant and gene therapy for thalassemia. The second part will focus on fetal hemoglobin induction and new therapies as they relate to sickle cell thalassemia. We will be using a combination of case presentations, discussions, and audience participation. Seats are limited, register now.
Supported by an educational grant from ApoPharma
Thursday, April 27
Plasminogen: An Overlooked Protein Leading to Multiple Rare Diseases
This symposia will review clinical and diagnostic challenges, historical treatment approaches, and recent case experience treating congenital plasminogen deficiency with a novel, purified plasminogen therapy. The future availability of purified plasminogen may provide important therapeutic options in pediatric hematology.
Supported by Prometic Life Sciences
Education Theater (in Exhibit Hall)
Friday, April 28
Evolution of T-Cell–Based Immunotherapy for the Treatment of Cancer
Supported by Amgen
Routine Transfusion Experience in Pediatric Patients Using Pathogen-Reduced Platelets
Supported by Cerus Corporation